Zydus Cadila launches insomnia drug in US market; company's shares trade 1.48% lower at Rs 232.20

The Gujarat-based Zydus Cadila has more than 270 USFDA approvals and has filed over 360 abbreviated new drug applications (ANDAs), since it commenced filings in 2003-04

Press Trust of India July 24, 2019 12:09:06 IST
Zydus Cadila launches insomnia drug in US market; company's shares trade 1.48% lower at Rs 232.20
  • In a BSE filing, Zydus Cadila announced the launch of Ramelteon tablets, 8 mg upon receiving the final approval from the USFDA. Ramelteon is a sedative, also called a hypnotic

  • Ramelteon is used to treat insomnia that is associated with having trouble falling asleep

  • Zydus Cadila said the drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad

New Delhi: Zydus Cadila on Wednesday launched Ramelteon tablets, used to treat insomnia, in the US market.

In a BSE filing, Zydus Cadila announced the "launch of Ramelteon tablets, 8 mg upon receiving the final approval from the USFDA. Ramelteon is a sedative, also called a hypnotic".

Ramelteon is used to treat insomnia that is associated with having trouble falling asleep.

Zydus Cadila said the drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The Gujarat-based group has more than 270 USFDA approvals and has filed over 360 abbreviated new drug applications (ANDAs), since it commenced filings in 2003-04.

Shares of Cadila Healthcare, the groups listed entity, were trading 1.48 percent lower at Rs 232.20 apiece on BSE.

Updated Date:

also read

AstraZeneca's COVID antibody drug shows reduction in severe infection, death in its phase 3 trials
science

AstraZeneca's COVID antibody drug shows reduction in severe infection, death in its phase 3 trials

The treatment - AZD7442 - is made from a combination of two antibodies and was given to 903 participants with 90 percent of them having a high risk of progression to severe COVID-19.

No bail for Aryan Khan today, hearing to resume tomorrow; probe reveals his involvement, says NCB
India

No bail for Aryan Khan today, hearing to resume tomorrow; probe reveals his involvement, says NCB

The NCB in its affidavit also said that Aryan Khan was in touch with some persons, who appear to be a part of an international drug network for procurement of drugs.

AstraZeneca seeks FDA's emergency use approval for its COVID-19 antibody treatment drug
science

AstraZeneca seeks FDA's emergency use approval for its COVID-19 antibody treatment drug

Late-stage human trials showed that AstraZeneca’s antibody drug reduced the risk of developing symptomatic COVID-19 by 77 percent.